Catalym

CatalYm offers answers to frequently asked questions about its ongoing clinical trials for cancer treatments.

GDF-15 is overexpressed in most solid tumors, supporting visugromab’s broad therapeutic potential in oncology.

CatalYm provides information about its clinical trials, focus indications, and the development of visugromab for cancer patients and healthcare providers.

CatalYm advances visugromab, a neutralizing antibody, for solid tumor indications with high medical need, targeting therapy resistance and cancer-associated cachexia.

Dr. Manfred Ruediger steps down as Chief Executive Officer of CatalYm • Dr. John Haurum succeeds Dr. Holger Reithinger as Chairman of the Supervisory Board

CatalYm GmbH appoints Phil L’Huillier as Chief Executive Officer, effective May 17, 2021. L’Huillier has over two decades of leadership experience in pharmaceutical and biotechnology industries.

Munich/Germany, November 10th, 2020 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round.

Alexander Eggermont is General Director of Gustave Roussy Cancer Institute, Professor of Oncology at Paris-Sud University, and Professor of Oncological Surgery at Erasmus University of Rotterdam. He holds an Honorary Chair at Louvain Catholic University and an Honorary Doctorate at Essen-Duisburg University.

Hans van Eenennaam is CEO and founder of IMMIOS and Chief Scientific Officer at Sairopa. He previously served as Chief Scientific Officer of AIMM Therapeutics and Executive Vice President of Antibody Research at Aduro Biotech Europe. Van Eenennaam co-founded BioNovion in 2011 and was its Chief Operational Officer.

Ignacio Melero is Professor of Immunology at the University of Navarra and the Center for Applied Medical Research. His research focuses on cancer immunotherapies using cell, gene, and monoclonal antibody strategies.

Professor Wischhusen is scientific co-founder of CatalYm. He is also the Head of the Section of Experimental Tumor Immunology at the University of Würzburg Medical School, Germany. Prof. Wischhusen’s current research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance. Previously, he was a research group leader at the Interdisciplinary Center for Clinical Research in Würzburg. He rec

CatalYm identifies GDF-15 as a cancer therapy resistance mechanism and develops visugromab, a neutralizing antibody. The company’s lead candidate demonstrates anti-tumor efficacy in solid tumor patients when combined with anti-PD-1 therapy.

CatalYm GmbH Am Klopferspitz 19 82152 Martinsried, Planegg Germany

CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors.

CatalYm GmbH Am Klopferspitz 19 82152 Planegg-Martinsried

CatalYm’s **Phase 2 GDFATHER-NEO trial** demonstrates that **visugromab**, a GDF-15 blockade therapy, significantly boosts the tumor-fighting effects of **nivolumab (PD-1 inhibitor)** in **neoadjuvant bladder cancer treatment**. The findings, presented at **ESMO 2026** and published in *Nature Medicine*, highlight improved clinical responses when combining the two therapies. The study marks a potential advancement in pre-surgical bladder cancer care by enhancing immunotherapy efficacy.

Oct 2026CatalYmNews article

CatalYm presents updated Phase 2 clinical data for its **GDFATHER-NEO trial** at **ESMO 2026**, featuring a rapid oral presentation. The company also highlights ongoing **Phase 2b trials for visugromab**, an investigational therapy. The event runs October 23–27 in Madrid, Spain.

Oct 2026CatalYmNews article

CatalYm names **Peter Garcia** as its new **Chief Financial Officer (CFO)**. He joins with over **three decades of experience** in biotechnology and oncology finance, specializing in **transformative financings, strategic transactions, and scaling global finance teams** for clinical development and commercialization.

Jun 2026CatalYmNews article

CatalYm names **Christian S. Schade** as Chairman of the Board, bringing over 30 years of biopharma leadership experience. The appointment follows the company’s initiation of **four late-stage clinical trials** for its lead candidate, **visugromab**, a GDF-15 inhibitor. Schade’s expertise aims to guide CatalYm during this pivotal phase of development.

Apr 2026CatalYmNews article